Haemonetics Q2 2024 Adj EPS $0.99 Beats $0.89 Estimate, Sales $318.18M Beat $313.12M Estimate
Portfolio Pulse from totan@benzinga.com
Haemonetics (NYSE:HAE) reported Q2 2024 earnings of $0.99 per share, beating the analyst consensus estimate of $0.89 by 11.24%. This is a 19.28% increase from the same period last year. The company also reported quarterly sales of $318.18 million, beating the analyst consensus estimate of $313.12 million by 1.62%, a 6.96% increase from the same period last year.
November 02, 2023 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Haemonetics reported better than expected Q2 2024 earnings and sales, which could positively impact its stock price in the short term.
Haemonetics reported higher than expected earnings and sales for Q2 2024. This positive financial performance could increase investor confidence and demand for the stock, potentially driving its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100